June 2026 Research Update

Taken together, these papers show how diagnosis is increasingly shaped by (1) looking for specific repeat expansions, (2) expanding testing when standard panels are negative, and (3) carefully documenting features like eye-movement changes and brain scan patterns that can point to the right gene. The strongest evidence in this set comes from a large review of one genetic subtype, while several other papers are single-patient or single-family reports that mainly expand awareness of what can show up in real life. [1] [2] [3]

For spinocerebellar ataxia type 27B (SCA27B), a global review of 1,267 genetically confirmed people found gait ataxia and eye-movement problems were very common, with speech changes and episodes of symptoms also frequently reported. It also found that larger repeat sizes (250 repeats or more) were linked to higher odds of gait ataxia and dysarthria, although results varied across studies. [1]

A smaller cross-sectional study of 18 adults with SCA27B added that symptoms can extend beyond balance and coordination, including other movement-disorder features and frequent cognitive changes consistent with a cerebellar cognitive-affective syndrome. About one-third had previously been misdiagnosed as having a transient ischemic attack, and a few had more than one repeat-expansion condition identified. [4]

In undiagnosed ataxia, a US screening study used a high-throughput test to look for the ZFHX3 repeat expansion that causes SCA4, confirming the expansion in three families and linking two to a Swedish founder haplotype. When the researchers then used haplotype-based screening in an additional 852 people (1,539 total), they did not find more SCA4 cases, suggesting this cause may be uncommon in that setting. [3]

Several single-family or single-patient reports highlighted how genetic diagnoses may appear in new populations or after earlier testing did not provide answers. One report described the first SCA10 family identified in Guatemala with a confirmed ATXN10 repeat expansion, and it included preliminary biomarker data showing higher neurofilament light chain in spinal fluid in the index case compared with unaffected/healthy comparisons. [5]

Another case report described the first SCA50 case from the Indian subcontinent, in a 22-year-old man with progressive ataxia, eye-movement abnormalities, mild cerebellar shrinkage on imaging, and an NPTX1 gene mutation. This kind of report cannot estimate how often SCA50 occurs, but it broadens the known geographic and clinical context for this rare subtype. [6]

Two additional case reports focused on diagnostic confusion and how added testing clarified it. In one, a woman with progressive gait and speech problems had unremarkable imaging and a negative panel for common SCA genes, but detailed video-based eye-movement testing showed a distinctive pattern and whole-exome sequencing identified a PRNP mutation causing Gerstmann-Straussler-Scheinker syndrome. [2]

In another, a man with episodic ataxia had extensive white-matter changes on MRI that led to confusion with multiple sclerosis, but genetic testing confirmed episodic ataxia type 2 due to a CACNA1A mutation. The report also described reduced episode frequency and severity with acetazolamide and trigger avoidance, but this was a single patient and does not predict response for everyone. [7]

One early-stage diagnostic study tested whether low-cost motion tracking could help distinguish conditions that can look similar. Using a Raspberry Pi-based system to measure reaching movements, researchers reported machine-learning accuracy of 83.3% when separating SCA12 from essential tremor in a small group, suggesting a possible future tool for supportive assessment or remote monitoring. [8]

Finally, a retrospective study in a movement-disorders clinic looked at people with slowly progressive chorea and no known family history and found genetic testing identified a cause in 30 of 36 tested patients. Although this paper is about chorea rather than cerebellar ataxia, it reinforces a broader point relevant to diagnostic workups in overlapping movement symptoms: genetic causes can still be common even when family history is negative. [9]

A veterinary case report described a Belgian Malinois puppy with early-onset ataxia and white-matter disease, where whole-genome sequencing found a recessive NECAP1 variant not seen in 158 breed controls. While this does not directly change human diagnosis, it adds background evidence that specific gene changes can produce ataxia-like syndromes across species and may inform future research into mechanisms. [10]

For patients and caregivers, this set of studies mainly matters as context for why an ataxia diagnosis can take time and may evolve as testing improves: different genetic subtypes can look alike, and some are rare in particular regions or ancestry groups. The most immediately useful knowledge is that certain patterns (like specific eye-movement findings, episodic symptoms, or confusing MRI changes) may push clinicians to consider broader or different genetic tests, while newer digital movement measures and biomarkers (like neurofilament light chain) are still early and not yet proven for routine use across all ataxias.

Across this set of studies, researchers focused on objective ways to measure disease changes in spinocerebellar ataxia (SCA) that could be used in clinical trials, especially measures that might pick up change earlier or more consistently than symptom scores alone. The overall direction was that several brain-based measures differed from healthy controls and also related to how severe symptoms were, but most evidence here is cross-sectional (one time point), so it is less clear how well they track change over time. [11] [12] [13] [14]

A multinational working group issued disease-specific recommendations for choosing magnetic resonance imaging (MRI) measures as trial end-points in SCA1, SCA2, SCA3, and Friedreich ataxia, and it also spelled out key gaps where more research is still needed. This kind of consensus work aims to help different studies collect brain scans in more comparable ways, so results can be interpreted more consistently across sites and trials. [11]

In an early-stage SCA2 and SCA3 multisite study using a harmonized brain scan method that measures brain chemicals (MR spectroscopy), several chemicals differed from controls in the cerebellum and pons, including lower tNAA and glutamate and higher myo-inositol and total creatine. The ratio tNAA to total creatine had the strongest links with clinical outcomes, and the most informative brain region differed by gene type (stronger cerebellum links in SCA2 and stronger pons links in SCA3). These results support using genotype-informed chemical measures as trial end-points, while noting that scanner differences required statistical adjustment. [12]

In a large multicenter SCA3 study, researchers found a specific pattern in the dorsolateral putamen where the usual relationship between brain structure and brain function was "decoupled," and this related to motor severity scores. The authors reported this pattern was independent of brain shrinkage (atrophy) and also overlapped with maps tied to mitochondrial function, certain serotonin receptor densities, and gene activity patterns linked to synapses and cell stability, suggesting a biologically grounded imaging marker for SCA3. [13]

In a small cross-sectional SCA2 study, an EEG brainwave measure called the auditory P300 differed by depression status and also differed between SCA2 and controls, with longer timing (latency) and smaller size (amplitude) linked to more depressive symptoms. These P300 measures correlated with depression scores but not with ataxia severity, suggesting they may reflect mood symptoms rather than movement symptoms in SCA2. [14]

For patients and caregivers, this research mostly matters now as background for how future SCA clinical trials may measure whether an experimental therapy is affecting the brain or specific symptoms. The studies suggest that (1) certain brain scan measures may be most informative in specific SCA types and brain regions, and (2) some measures may capture non-motor symptoms like depression separately from ataxia severity. What remains uncertain is how well these biomarkers change over time within the same person, how sensitive they are to treatment effects, and how consistently they can be used across hospitals and scanner types without affecting results.

Across these papers, researchers studied both supportive care (helping symptoms such as pain) and disease-focused approaches (aiming to change disease biology) in spinocerebellar ataxia. The overall pattern was improvement in movement or pain measures, while long-term brain tissue protection and real-world effectiveness in people remain uncertain because most results were from mouse studies or a single-person report. [15] [16] [17]

In a spinocerebellar ataxia type 1 (SCA1) mouse model, prolonged voluntary wheel-running improved motor ataxia but did not prevent cerebellar degeneration at the ages studied. The same study found exercise largely corrected abnormal RNA splicing patterns in the cerebellum, especially in groups of ion-channel related genes, making exercised SCA1 mice look more like controls at the RNA processing level. [15]

In a spinocerebellar ataxia type 3 (SCA3) mouse model, researchers used modified exosomes to deliver a microRNA (miRNA) inhibitor to the brain, increasing DNAJB1 (a protein linked to clearing misfolded proteins). This approach reduced mutant ATXN3 clumping, improved nerve cell survival, and improved motor coordination, and the authors reported stronger effects when combined with another miRNA approach aimed at lowering ATXN3. [16]

One case report described a man with SCA3 and hard-to-treat neuropathic back pain who received scrambler therapy twice daily and reported sustained pain relief for eight weeks after 12 sessions. The report also noted reduced use of systemic pain medicine and improvements in sleep and mood, with no scrambler-related side effects reported in this single patient. [17]

For patients and caregivers, these studies mainly add background about what is being tested, rather than changing standard care today. The exercise and exosome-miRNA studies were in mice, so it is unknown how much they translate to people or whether they affect long-term disability or brain changes. The scrambler therapy report suggests a possible non-drug option for neuropathic pain in SCA3, but because it describes only one person without a comparison group, it is uncertain who might benefit and how long relief typically lasts. [15] [16] [17]

This retrospective hospital study highlights that some people initially treated as having an immune-driven cerebellar ataxia may later be reclassified as having a neurodegenerative ataxia, even after early testing and imaging. It also suggests that earlier presentation after symptom onset was linked with a better measured response to immunotherapy in this suspected autoimmune group. [18]

Among 24 patients considered suspected autoimmune cerebellar ataxia, 20 treated patients could be evaluated for response and 11 met the study definition of response (at least a 3-point improvement on a standardized ataxia score). Responders came to medical attention sooner after symptom onset than non-responders (12.0 vs 24.0 months). [18]

During follow-up, 8 of the 24 suspected autoimmune cases (33.3%) were later reclassified as having a neurodegenerative disease. Baseline imaging differences were reported between suspected autoimmune cases and the SCA/multiple system atrophy comparison group overall, but baseline imaging did not clearly distinguish the patients who were later reclassified. [18]

For patients, this study is most relevant to situations where an immune cause of ataxia is being considered and immunotherapy is tried. It suggests that short-term improvement can occur in some people initially labeled suspected autoimmune ataxia, but that the diagnosis can shift over time, which may affect how families interpret early responses and test results. Because this was a retrospective, single-center review, it cannot tell which specific treatment is best or precisely predict outcomes for an individual. [18]

This months papers mainly used lab and animal models to look upstream of symptoms, at what may drive nerve cell dysfunction in spinocerebellar ataxias. Across different genetic forms and models, a repeated pattern was stress and injury in cerebellar circuits, including Purkinje cell damage, changes in supporting glial cells, and shifts in energy and protein-handling pathways. These are early-stage studies, so they help map possible biological routes to disease but do not show how often these changes occur in people or how they connect to day-to-day progression. [19] [20] [21] [22] [23] [24]

In a rat model where a chemical was used to trigger cerebellar degeneration, researchers saw severe movement problems alongside Purkinje cell loss and misplacement, lower levels of a key energy-related enzyme signal (cytochrome oxidase) in Purkinje cells, and lower synaptophysin (a marker linked to synapses) in cerebellar structures. Electron microscopy also showed ultrastructural changes in a subgroup described as dark-type Purkinje cells, supporting this as a model for studying cerebellar cortex degeneration. [19]

Using patient-derived induced pluripotent stem cells (hiPSCs) from spinocerebellar ataxia type 7 (SCA7), one study reported that lab-made astrocytes (support cells in the brain) lost typical astrocyte markers (GFAP and S100B) and showed broad gene expression changes. The altered genes related to glial development, metabolism and oxygen handling, protein homeostasis, and neuronal development and signaling, and mitochondrial stress testing supported a mitochondrial phenotype in SCA7 neural cells. [20]

A mouse model that reduced TG6 (a protein made from the TGM6 gene, linked to some ataxias) showed motor coordination problems mainly in males, starting around mid-life in the study. Females were largely unaffected, and the authors noted evidence suggesting possible compensation by another related gene (Tgm4) in females, but the reason for this sex difference was not clear. [21]

In lab membrane systems, variants of Dynorphin A linked to spinocerebellar ataxia type 23 (SCA23) were reported to be recruited to membranes by electrical charge interactions, then insert and form short-lived pores in a mutation-dependent way. Membranes with more negatively charged lipids were easier to disrupt, while cholesterol reduced the peptides activity in a variant-specific way, and the variants also changed how amyloid-beta assembled by increasing hydrophobic surface exposure without a matching increase in fibril formation. [22]

One molecular study cataloged many human RNAs with CAG repeat stretches and focused on circular RNAs (circRNAs) from the ATXN7 region. It reported that a specific circRNA was found in the cell fluid (cytoplasm), was present in ribosome-associated fractions, and was detectable in fibroblasts, blood, and cerebellum, and it also identified a mutation-containing circRNA that could be relevant to SCA7 biology. [23]

Finally, researchers created and characterized two patient-derived iPSC lines from people with FGF14-related ataxia (one SCA27A and one autosomal recessive), providing a tool to study how FGF14 deficiency affects nerve cells after these stem cells are turned into relevant brain cell types. This work is mainly a research resource rather than a test of a disease mechanism by itself. [24]

For patients and caregivers, these papers mainly add background about possible drivers of ataxia biology rather than changing care now. They suggest that multiple routes can lead to cerebellar dysfunction, including Purkinje cell injury, altered astrocyte identity and mitochondria, and membrane disruption that depends on the exact gene variant, and even on sex in one mouse model. What remains uncertain is how well each lab model matches what happens in different people with ataxia, and which of these changes are causes versus downstream effects of ongoing disease.

Across these studies in spinocerebellar ataxia type 3 (SCA3), two different kinds of possible disease modifiers were examined: body hormone patterns and a specific DNA variant. The overall picture was mixed, with one thyroid-related measure linking to faster symptom worsening, while one proposed genetic modifier showed no clear effect on when symptoms began.

In an observational study of ATXN3 gene carriers with normal thyroid status (including people before and after ataxia symptoms), lower values of a thyroid hormone balance measure (the fT3/fT4 ratio) were tied to faster worsening of motor scores over time. Thyroid-related differences were also detectable even before ataxia onset, suggesting thyroid hormone regulation may be one contributor to why SCA3 progression differs between people. [25]

In a separate Japanese genetic study, the PRKN V380L (rs1801582) variant did not show an independent link to age at onset after accounting for ATXN3 repeat length and sex, and the C/C genotype was extremely rare. In the same analysis, longer ATXN3 CAG repeat length still strongly predicted earlier symptom onset. [26]

For patients and caregivers, these results mainly add background information about why SCA3 can look different from person to person. The thyroid study suggests that routine blood hormone measures might relate to how quickly coordination symptoms change, but it does not prove that thyroid differences cause faster progression, and it is not yet a tool used to guide care. The genetic study is useful as a reality check that not every suggested DNA modifier holds up in larger or different populations, and it reinforces that ATXN3 repeat length remains a key factor linked to when symptoms start, while other modifiers are still being tested.

Across available population data, deaths recorded as hereditary ataxias have been increasing over the past two decades in the United States, and projections suggest this upward trend may continue. The pattern was not uniform across groups, with larger increases reported in some populations and regions. Important uncertainties remain because these results depend on how causes of death are coded and because forecasts are less certain when broken down into smaller subgroups. [27]

Using US national death records from 2000 to 2020 (ICD-10 code G11), the study found that the overall age-adjusted death rate for hereditary ataxias increased over time. In the same dataset, death rates were consistently higher in males, and the largest relative increases were reported among Black or African American individuals and in the West census region. Forecasting analyses in this study also suggested mortality may keep rising through 2050. [27]

The authors noted that death-certificate coding can blur important differences between specific types of ataxia, and that this can affect trend estimates. They also highlighted that projections, especially within subgroups, come with wider uncertainty and should be interpreted cautiously. They called for better clinical characterization and registry-linked tracking to improve understanding of long-term outcomes. [27]

For patients and caregivers, this study mainly provides background about how hereditary ataxias are showing up in national death statistics, rather than information about an individual person's outlook. The reported differences by sex, race, and region suggest that population-level impacts may not be evenly shared, but the reasons for these differences cannot be determined from death records alone. A key uncertainty is whether changing diagnosis and coding practices over time contributed to the observed increases, which is why improved tracking systems were highlighted as a need. [27]